← Back to headlines
Radiopharm Schedules FDA Meeting for Brain Imaging Agent RAD101
Radiopharm has scheduled a meeting with the FDA regarding its brain imaging agent, RAD101.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
